SCHEMBL6799310

SCHEMBL6799310

COc1ccc(-c2ncc(NC(=O)c3ccccc3)c(=O)n2CC(=O)O)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.54
NPC1 O15118 3/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
KDM4E B2RXH2 1/20 0.54
TP53 P04637 1/20 0.54
ELANE P08246 3/20 0.52
ALDH1A1 P00352 3/20 0.52
HDAC2 Q92769 1/20 0.48
F10 P00742 1/20 0.47
PKM P14618 1/20 0.46
CASP1 P29466 1/20 0.46
SNCA P37840 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
HSP90AA1 P07900 1/20 0.45
HSP90AB1 P08238 1/20 0.45
F2 P00734 1/20 0.45
DEGS1 O15121 1/20 0.44
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6805801 0.89 RAB9A (0.53) RAB9ANPC1SMN1; SMN2KDM4ETP53
SCHEMBL6240894 0.89 ELANE (0.51) RAB9ANPC1SMN1; SMN2KDM4ETP53
SCHEMBL6803676 0.88 RAB9A (0.52) RAB9ANPC1SMN1; SMN2ELANEHDAC2
SCHEMBL6801188 0.86 SMN1; SMN2 (0.48) RAB9ANPC1SMN1; SMN2KDM4ETP53
SCHEMBL6805612 0.86 HDAC2 (0.46) RAB9ANPC1SMN1; SMN2TP53ELANE
SCHEMBL6803430 0.86 ALDH1A1 (0.52) RAB9ANPC1SMN1; SMN2KDM4EELANE
SCHEMBL6802993 0.86 RAB9A (0.52) RAB9ANPC1SMN1; SMN2KDM4EELANE
SCHEMBL6805617 0.85 SMN1; SMN2 (0.48) RAB9ANPC1SMN1; SMN2KDM4ETP53
SCHEMBL6556284 0.84 ELANE (0.71) ELANE
SCHEMBL6805406 0.83 HSP90AA1 (0.47) RAB9ANPC1SMN1; SMN2KDM4ETP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063936-A1 Pyrimidine derivatives and process for preparing the same ONO PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 US claimed
EP-1346985-A1 PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP claimed
US-20040063936-A1 Pyrimidine derivatives and process for preparing the same ONO PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 US disclosed
EP-1346985-A1 PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063936-A1 Pyrimidine derivatives and process for preparing the same DPYD, NUDT1, UMPS RAB9A 2244/4885NPC1 1638/4885SMN1; SMN2 1296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.